GlassScriptPhysician profile
Christopher Khalil Clarke
NPI 1295120210
$4,552.72
in general payments reported to CMS, 2019-2025
33 companies · $65.29 in 2025
The $65.29 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $807 · 2020: $145 · 2021: $471 · 2022: $1,356 · 2023: $1,576 · 2024: $134 · 2025: $65.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,775.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,775.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $736.49 | 2021-2023 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $683.72 | 2019-2023 | Rybelsus, Ozempic, Tresiba |
| Astrazeneca Pharmaceuticals LP | $487.21 | 2019-2023 | Farxiga, Breztri |
| Abbott Laboratories | $421.62 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $321.85 | 2019-2023 | Repatha, Otezla |
| Lilly USA, LLC | $300.48 | 2022-2023 | Mounjaro, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $269.82 | 2019-2023 | Xifaxan |
| Glaxosmithkline, LLC. | $249.09 | 2021-2023 | Shingrix, Arexvy |
| Pfizer INC. | $245.61 | 2019-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $97.86 | 2022 | |
| Dexcom, INC. | $82.93 | 2021-2023 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $76.04 | 2019-2023 | Trintellix |
| Esperion Therapeutics, INC. | $57.90 | 2021-2023 | Nexletol |
| Exact Sciences Corporation | $56.83 | 2023 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $55.75 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.64 | 2023 | Synjardy, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $49.19 | 2023 | |
| Amarin Pharma, INC. | $46.42 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $42.09 | 2022 | |
| Janssen Pharmaceuticals, INC | $26.24 | 2019-2024 | Xarelto |
| Atricure, INC. | $25.34 | 2023 | |
| Corium, LLC | $20.52 | 2023 | Azstarys |
| Halozyme INC | $18.59 | 2023 | |
| Bausch Health US, LLC | $18.12 | 2022 | |
| Idorsia Pharmaceuticals US INC | $17.91 | 2023 | Quviviq |
| Axsome Therapeutics, INC. | $17.63 | 2023 | Auvelity |
| Ascensia Diabetes Care US INC. | $15.01 | 2023 | |
| Insmed, INC. | $13.00 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.52 | 2019 | |
| Intuitive Surgical, INC. | $11.42 | 2019 | |
| Amneal Pharmaceuticals LLC | $11.29 | 2021 | |
| Genentech USA, INC. | $10.89 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $4.70 | 2024 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Clarke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.